Famciclovir
From Wikipedia, the free encyclopedia
Famciclovir
|
|
Systematic (IUPAC) name | |
[2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)-butyl] acetate | |
Identifiers | |
CAS number | 104227-87-4 |
ATC code | J05AB09 S01AD07 |
PubChem | 3324 |
DrugBank | APRD00600 |
Chemical data | |
Formula | C14H19N5O4 |
Mol. weight | 321.332 g/mol |
Physical data | |
Melt. point | 103 °C (217 °F) |
Pharmacokinetic data | |
Bioavailability | 75–77% |
Protein binding | 20-25% |
Metabolism | Hepatic, circulation, intestinal wall (to penciclovir) |
Half life | 2–2.3 hours |
Excretion | Renal, faecal |
Therapeutic considerations | |
Pregnancy cat. | |
Legal status |
S4 (Au), POM (UK), ℞-only (U.S.) |
Routes | Oral |
Famciclovir (INN) (IPA: [pɛnˈsaɪklovir]) is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).
[edit] See also
Antivirals (primarily J05A, also S01AD and D06BB) edit | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|